Contribution
My Lords, I congratulate the noble Baroness, Lady Deech, on securing this debate today and airing the issues—which clearly need airing—and I thank all noble Lords for their contributions. There is probably only one thing that unites all the contributions, which is concern for the safety and well-being of children and young people. There is, of course, considerable difference of opinion among contributors.
I start by making it clear that the government policy on care for children and young people with gender incongruence is underpinned by the absolute need for them to receive safe care based on evidence, which is what will always drive us. That is why we are implementing the Cass review. I am most grateful to the noble Baroness, Lady Cass, not just for conducting the review but for her continued work and indeed for her contribution today. In many ways, she has saved me something of a job by setting out the facts, as she did when she previously wrote to all noble Lords, so I will not repeat a number of those points.
We are implementing the Cass review and transforming children and young people’s gender services. These services, including the four new services that are now operating, with plans for provision in every region of England by the end of 2027-28, provide a holistic model of care, with a focus on psychosocial support, which the noble Baroness, Lady Deech, asked about. The service specification for these services is quite clear that medical intervention is not the standard approach to care.
If we look back to March 2024, it was then that NHS England issued a clinical policy which set out that puberty-supressing hormones are not available for routine commissioning within the gender services. This followed a number of evidence reviews that did not identify good enough evidence about safety, risks, benefits and outcomes. The Cass Review, which was commissioned under the previous Government, was published in April 2024 and also found that there was insufficient evidence.
The then Health Secretary, Victoria Atkins, welcomed the review and committed to implementing its recommendations. There was an introduction of an emergency order restricting the private sale and supply of puberty-suppressing hormones for gender incongruence—I believe the noble Lord, Lord Frost, welcomed that action, as indeed I did, not least because this Government picked that up and extended the restrictions, making them indefinite from January 2025. I remind your Lordships’ House that the decision was upheld in the High Court when it was challenged.
The decision in respect of implementing recommendations and the response on puberty-suppressing hormones was taken with great care. It was informed by a wide range of evidence, including a report from the independent Commission on Human Medicines, which indicated that young people with gender incongruence and dysphoria were uniquely being exposed to potential safety risks. I listened closely to all the contributions, but I believe the noble Baroness, Lady Murphy, set out why doing nothing is not a neutral option, which the noble Baroness, Lady Barker, referred to. To put it in my own non-medical language, the issue does not go away by doing nothing.
Regarding the PATHWAYS study, which a number of noble Lords have referred to, the Cass review drew attention to how we need better evidence. We must be able to inform clinical decisions with—I shall reuse my words, looking at the noble Baroness, Lady Buscombe—a cool head. I hope that the evidence will inform the decisions made by children and their families.
NHS England and DHSC, through the National Institute for Health and Care Research, worked to design and fund a research programme. It includes a regularly updated, systemic review of available research evidence and, I say to the noble Baroness, Lady Deech, a data linkage survey study—not an either/or but both—as well as the PATHWAYS study. The trial has been approved by the Health Research Authority and the MHRA. We are talking about a trial involving a small number of children and young people who are already receiving the support of NHS gender services.
The noble Baronesses, Lady Deech and Lady Meyer, raised the PATHWAYS trial entry age. This has been reviewed by the MHRA and the study sponsor, resulting in a minimum age for trial participation of 11 for biological females and 12 for biological males. It is right that this Government, like the previous Government or any Government, are guided by expert clinical and scientific advice and take that approach.
The noble Baronesses, Lady Deech and Lady Meyer, asked about eligibility for the PATHWAYS trial, which it tightly controls. It requires individual assent and parental consent—I am glad that the noble Baroness, Lady Deech, referred to the Gillick principle. It also requires a minimum two-year gender incongruence diagnosis, ongoing access to psychosocial support and NHS clinician and multidisciplinary team approval, as well as participant understanding of risks and benefits, physical and mental stability and compliance with safeguarding requirements. I do not consider that to be anything less than a properly considered and evidence-based approach to ensure that we can provide the healthcare that is needed.
Questions were raised about parental consent. That is integral. The parent or legal guardian must agree to their child’s involvement. There is no requirement to be a participant, as has been suggested; these people are coming forward. They must also meet the very stringent issues that are put to them. I say to the noble Baroness, Lady Cash, and other noble Lords that children who have gender incongruence deserve to be able to participate in research, as they also deserve evidence-based care, as we all do, in the same way as children with other clinical diagnoses.
Masculinising and feminising hormones were referred to in the debate. Following an independent review of evidence, NHS England has launched a consultation which has proposed that these should no longer be available as a routine commissioning option. The outcome of the consultation is under consideration. We will return to that.
I conclude by saying that maintaining the safety and well-being of children and young people is our priority and always will be, and I must emphasise that it will always be rooted in evidence.